BODY
DHEA Topical and Vaginal in Postmenopause — Prasterone (Intrarosa) as a New Option for Skin, Collagen, Vaginal Atrophy
DHEA (dehydroepiandrosterone) is an adrenal androgen + estrogen precursor. Production declines ~1-2% yearly from late 30s, dropping sharply after menopause. Topical DHEA shows skin collagen + hydration benefit; vaginal Prasterone (Intrarosa, FDA-approved 2016) effectively treats postmenopausal vaginal atrophy. Safe up to 50 mg daily, but absolutely contraindicated in hormone-sensitive cancer + monitor androgen side effects (acne, hirsutism).
The Data
Topical DHEA (Skin)
- Daily topical → skin hydration, collagen synthesis, thickness improvements reported
- Slows age-related skin thinning
- Stronger effect in postmenopausal women
Oral DHEA (Systemic)
- 50 mg daily for 6 months → modest skin/mood/strength improvements
- DARE meta-analysis: limited confidence in normal-adrenal-function postmenopausal women
- Some studies show mild improvement in sexual function (desire, arousal, lubrication)
Vaginal Prasterone (Intrarosa)
- 6.5 mg daily vaginal suppository
- 12 weeks → significant improvement in vaginal atrophy, pain, lubrication
- FDA-approved 2016 (vaginal atrophy indication)
- Korean adoption in progress
Safety Range
- Up to 50 mg daily: safe data through 2 years
- Long-term (5+ years): data limited
- Side effects: acne, hirsutism, mood swings (androgenic)
- Contraindications: breast, ovarian, endometrial cancer, pregnancy/lactation
Multi-Axis Action
Hormone Precursor
- DHEA → androstenedione → testosterone → estradiol
- Partially restores residual estrogen/testosterone pool postmenopause
- Local conversion in adrenal + skin + vaginal mucosa
Skin Effects
- Stimulates fibroblasts → collagen + elastin synthesis
- Increases epidermal thickness + hydration
- Stimulates sebaceous glands (androgenic)
- Partially blocks MMP collagen degradation
Vaginal Effects
- Mucosal thickness + lubrication restoration
- Vaginal pH normalization → microbiome recovery
- Frequency, pain, dyspareunia improvement
Mood + Cognition
- Some clinical mild depression + cognitive improvement
- Mixed data
”DHEA = Universal Anti-Aging” Perception vs Data
Marketing Tone
- “Hormone of youth”
- “Anti-aging panacea”
- “Natural testosterone boost”
→ Possibly overstated.
Clinical Data Tone
- Topical DHEA: limited skin data
- Oral DHEA: mixed effect in normal-adrenal-function
- Vaginal Prasterone: clear indication (vaginal atrophy)
- Safe range 50 mg/day, 2 years
→ Target-specific use.
Self-Assessment
Consider DHEA:
- 5+ years post-menopause
- Adrenal hypofunction (DHEA-S labs)
- Vaginal atrophy + lubrication deficit + pain
- Skin thinning + collagen loss
- Chronic stress + adrenal fatigue suspicion
Avoid:
- Hormone-sensitive cancer diagnosis or family history
- Pregnancy/lactation
- Active acne/hirsutism
- PCOS (excess androgen state)
Korean Market Position
In Korea:
- Oral DHEA: pharmaceutical category, prescription required (overseas direct purchase common)
- Topical DHEA: cosmetic exclusion, pharmaceutical territory
- Prasterone (Intrarosa): MFDS adoption in progress, postmenopausal atrophy indication
Alternatives:
- Tongkat ali: mild testosterone stimulus (supplement)
- Maca: estrogen + libido modulator (supplement)
- Black cohosh: phytoestrogen
- Topical estradiol (prescribed): hormone replacement
Clinical Application
- Bloodwork: DHEA-S, free testosterone, estradiol, FSH, LH
- Topical: 5-10% DHEA (prescribed, not registered in Korea)
- Vaginal: Prasterone 6.5 mg daily suppository (FDA-approved, Korean adoption pending)
- Oral: 25-50 mg daily (with physician guidance, hormone-sensitive cancer family history pre-screened)
- Monitoring: 3-month DHEA-S + testosterone + symptom assessment
- Side effect signals: acne, hirsutism, mood swings → discontinue
- Synergy stack: DHEA + vitamin D + estrobolome + protein + resistance training
- 6-month review: discontinue if no effect, reassess at 1-2 years if effective
- Long-term gap: 5+ year data limited, regular reassessment essential